BioMarin Pharmaceutical Inc. announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease.
- Read the complete press release here (external Link)
- Read a print version of the press release at BioMarin (external Link)
- Download a copy of the press release from the IPA website (PDF, 107 kB)